Systemic and pituitary pars intermedia antioxidant capacity associated with pars intermedia oxidative stress and dysfunction in horses

American Journal of Veterinary Research

Volumn 66, Issue 12, 2005, Pages 2065-2072

  McFarlane, Dianne ^a   Cribb, Alastair E ^a  

^a UNIVERSITY OF PRINCE EDWARD ISLAND   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; ANTIOXIDANT; FORMALDEHYDE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; MANGANESE SUPEROXIDE DISMUTASE; PARAFFIN; SUPEROXIDE DISMUTASE;

ADRENAL GLAND; AGE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD ANALYSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE PREDISPOSITION; ENZYME ACTIVITY; ERYTHROCYTE; FEMALE; HORSE DISEASE; HYPOPHYSIS DISEASE; HYPOPHYSIS INTERMEDIATE LOBE; MALE; NONHUMAN; OXIDATIVE STRESS; PROTEIN ANALYSIS; STATISTICAL SIGNIFICANCE; SUBSTANTIA NIGRA; SYSTEMIC DISEASE;

AGE FACTORS; ALPHA-MSH; ANIMALS; ANTIOXIDANTS; ERYTHROCYTES; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HORSE DISEASES; HORSES; OXIDATIVE STRESS; PITUITARY DISEASES; PITUITARY GLAND; SUPEROXIDE DISMUTASE; TYROSINE;

ANIMALIA; EQUIDAE; EQUUS CABALLUS;

EID: 33645240228     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2005.66.2065     Document Type: Article

References (36)

1. Hillyer MH, Taylor FRG, Mair TS, et al. Diagnosis of hyperadrenocortism in the horse. Equine Vet Educ 1992;4:131-134.
2. Love S. Equine Cushing's disease. Br Vet J 1993;149:139-153.
3. van der Kolk JH, Kalsbveek HC, van Garderen E, et al. Equine pituitary neoplasia: a clinical report of 21 cases (1990-1992). Vet Rec 1993;133:594-597.
4. van der Kolk JH, Wensing T, Kalsbeek HC, et al. Laboratory diagnosis of equine pituitary pars intermedia adenoma. Domest Anim Endocrinol 1995;12:35-39.
5. Schott HC. Pituitary pars intermedia dysfunction: equine Cushing's disease. Vet Clin North Am Equine Pract 2002;18:237-270.
6. Millington WR, Dybdal NO, Dawson R, et al. Equine Cushing's disease: differential regulation of β-endorphin processing in tumors of the intermediate pituitary. Endocrinology 1988;123:1598-1604.
7. Donaldson MT, LaMonte BH, Morresey P, et al. Treatment with pergolide or cyproheptadine of pituitary pars intermedia dysfunction (equine Cushing's disease). J Vet Intern Med 2002;16:742-746.
8. Orth DN, Holscher MA, Wilson MG, et al. Equine Cushing's disease: plasma immunoreactive proopiolipomelanocortin peptide and cortisol levels basally and in response to diagnostic tests. Endocrinology 1982;110:1430-1441.
9. Schott HC, Coursen CL, Eberhart SW, et al. The Michigan Cushing's Project, in Proceedings. 47th Annu Conv Am Assoc Equine Pract 2001;47:22-24.
10. McFarlane D, Dybdal N, Donaldson MT, et al. Nitration and increased alpha-synuclein expression associated with dopaminergic neurodegeneration in equine pituitary pars intermedia dysfunction (PPID). J Neuroendocrinol 2005;17:73-80.
11. Calabrese V, Bates TE, Stella AM. NO synthase and NO-dependent signal pathways in brain aging and neurodegenerative disorders: the role of oxidant/antioxidant balance. Neurochem Res 2000;25:1315-1341.
12. Gilgun-Sherki Y, Melamed E, Offen D. Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier. Neuropharmacology 2001;40:959-975.
13. Luo Y, Roth GS. The roles of dopamine oxidative stress and dopamine receptor signaling in aging and age-related neurodegeneration. Antioxid Redox Signal 2000;2:449-460.
14. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of aging. Nature 2000;408:239-247.
15. Farrer M, Maraganore DM, Lockhart P, et al. α-Synuclein gene haplotypes are associated with Parkinson's disease. Hum Mol Genet 2001;10:1847-1851.
16. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047.
17. Saha AR, Ninkina NN, Hanger DP, et al. Induction of neuronal death by α-synuclein. Eur J Neurosci 2000;12:3073-3077.
18. Giasson BI, Duda JE, Murray IV, et al. Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions. Science 2000;290:985-989.
19. Marshall MD, Wattam SL, Skinner ND, et al. Feline antioxidant enzyme activity: the effect of sample storage on stability. J Nutr 2002;132:1733S-1734S.
20. McFarlane D, Donaldson MT, McDonnell SM, et al. Effects of season and sample handling on measurement of plasma α-melanocyte-stimulating hormone concentrations in horses and ponies. Am J Vet Res 2004;65:1463-1468.
21. Peskin AV, Winterbourn CC. A microtiter plate assay for superoxide dismutase using a water-soluble tetrazolium salt (WST-1). Clin Chim Acta 2000;293:157-166.
22. Tappel AL. Glutathione peroxidase and hydroperoxides. Methods Enzymol 1978;52:506-513.
23. Smith AD, Levander OA. High-throughput 96-well microplate assays for determining specific activities of glutathione peroxidase and thioredoxin reductase. Methods Enzymol 2002;347:113-121.
24. Tietze F. Enzymatic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem 1969;27:502-522.
25. Kojda G, Harrison D. Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc Res 1999;43:562-571.
26. Priyadarshi A, Khuder SA, Schaub EA, et al. Environmental risk factors and Parkinson's disease: a metaanalysis. Environ Res 2001;86:122-127.
27. Gillette JS, Bloomquist JR. Differential up-regulation of striatal dopamine transporter and alpha-synuclein by the pyrethroid insecticide permethrin. Toxicol Appl Pharmacol 2003;192:287-293.
28. Sherer TB, Betarbet R, Stout AK, et al. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J Neurosci 2002;22:7006-7015.
29. Kalra J, Rajput AH, Mantha SV, et al. Serum antioxidant enzyme activity in Parkinson's disease. Mol Cell Biochem 1992;110:165-168.
30. Schulz JB, Lindenau J, Seyfried J, et al. Glutathione, oxidative stress and neurodegeneration. Eur J Biochem 2000;267:4904-4911.
31. Kunikowska G, Jenner P. Alterations in m-RNA expression for Cu,Zn-superoxide dismutase and glutathione peroxidase in the basal ganglia of MPTP-treated marmosets and patients with Parkinson's disease. Brain Res 2003;968:206-218.
32. Krall J, Bagley AC, Mullenbach GT, et al. Superoxide mediates the toxicity of paraquat for cultured mammalian cells. J Biol Chem 1988;263:1910-1914.
33. Bianchi A, Becuwe P, Franck P, et al. Induction of MnSOD gene by arachidonic acid is mediated by reactive oxygen species and p38 MAPK signaling pathway in human HepG2 hepatoma cells. Free Radic Biol Med 2002;32:1132-1142.
34. Martin GM, Austad SN, Johnson TE. Genetic analysis of ageing: role of oxidative damage and environmental stresses. Nat Genet 1996;13:25-34.
35. Aigaki T, Seong KH, Matsuo T. Longevity determination genes in Drosophila melanogaster. Mech Ageing Dev 2002;123:1531-1541.
36. Guarente L, Kenyon C. Genetic pathways that regulate ageing in model organisms. Nature 2000;408:255-262.